Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Canakinumab> ?p ?o. }
Showing items 1 to 54 of
54
with 100 items per page.
- Canakinumab abstract "Canakinumab (INN, trade name Ilaris, previously ACZ885) is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.Canakinumab was approved for the treatment of cryopyrin-associated periodic syndromes (CAPS) by the U.S. Food and Drug Administration (FDA) on June 2009 and by the European Medicines Agency in October 2009. CAPS is a spectrum of autoinflammatory syndromes including familial cold autoinflammatory syndrome, Muckle–Wells syndrome, and neonatal-onset multisystem inflammatory disease.Canakinumab was being developed by Novartis for the treatment of rheumatoid arthritis but this trial was completed in October 2009. Canakinumab is also in phase I clinical trials as a possible treatment for chronic obstructive pulmonary disease, gout and coronary artery disease.".
- Canakinumab atcPrefix "L04".
- Canakinumab atcSuffix "AC08".
- Canakinumab casNumber "914613-48-2".
- Canakinumab drugbank "DB06168".
- Canakinumab fdaUniiCode "37CQ2C7X93".
- Canakinumab wikiPageExternalLink NCT01327846?term=NCT01327846&rank=1.
- Canakinumab wikiPageID "12148828".
- Canakinumab wikiPageRevisionID "585453832".
- Canakinumab atcPrefix "L04".
- Canakinumab atcSuffix "AC08".
- Canakinumab c "6452".
- Canakinumab casNumber "914613".
- Canakinumab chembl "1201834".
- Canakinumab chemspiderid "NA".
- Canakinumab drugbank "DB06168".
- Canakinumab h "9958".
- Canakinumab hasPhotoCollection Canakinumab.
- Canakinumab legalUs "Rx-only".
- Canakinumab licenceEu "Ilaris".
- Canakinumab licenceUs "Canakinumab".
- Canakinumab mabType "mab".
- Canakinumab molecularWeight "145.2".
- Canakinumab n "1722".
- Canakinumab o "2010".
- Canakinumab routesOfAdministration Intravenous_therapy.
- Canakinumab routesOfAdministration Subcutaneous_injection.
- Canakinumab s "42".
- Canakinumab source "u".
- Canakinumab target IL1B.
- Canakinumab tradename "Ilaris".
- Canakinumab type "mab".
- Canakinumab unii "37".
- Canakinumab verifiedfields "changed".
- Canakinumab verifiedrevid "460015774".
- Canakinumab subject Category:Novartis.
- Canakinumab type Drug.
- Canakinumab type DrugProduct.
- Canakinumab type FunctionalSubstance.
- Canakinumab comment "Canakinumab (INN, trade name Ilaris, previously ACZ885) is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.Canakinumab was approved for the treatment of cryopyrin-associated periodic syndromes (CAPS) by the U.S. Food and Drug Administration (FDA) on June 2009 and by the European Medicines Agency in October 2009.".
- Canakinumab label "Canakinumab".
- Canakinumab label "Canakinumab".
- Canakinumab label "Canakinumab".
- Canakinumab label "Canaquinumabe".
- Canakinumab label "كاناكينوماب".
- Canakinumab sameAs Canakinumab.
- Canakinumab sameAs Canakinumab.
- Canakinumab sameAs Kanakinumab.
- Canakinumab sameAs Canaquinumabe.
- Canakinumab sameAs m.02vrcld.
- Canakinumab sameAs Q3655009.
- Canakinumab sameAs Q3655009.
- Canakinumab wasDerivedFrom Canakinumab?oldid=585453832.
- Canakinumab isPrimaryTopicOf Canakinumab.